Amended Current Report Filing (8-k/a)
April 11 2022 - 06:16AM
Edgar (US Regulatory)
0000867028 true Amendment No. 1
0000867028 2022-04-07 2022-04-07 iso4217:USD xbrli:shares
iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 7, 2022
FOMO CORP.
(Exact
name of Registrant as specified in its Charter)
california |
|
001-13126 |
|
83-3889101 |
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
1 E Erie St,
Ste 525 Unit #2250,
Chicago,
IL
60611
(Address
of principal executive offices)
(630)
286-9560
(Registrant’s
Telephone Number)
(Former
name or address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common |
|
FOMC |
|
OTC Pink |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2)
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act
FOMO
CORP. is referred to herein as “FOMO”, the “Company”, “we”, or
“us”.
Background
This
Amendment to Form 8-K filed April 8, 2022 includes a statement of
holdings in GenBio, Inc. held by FOMO. It does not reflect a
$25,000 venture loan convertible into 25,000 common shares
associated with a financing completed on October 7, 2021. The
statement of holdings is included herein as Exhibit
10.1.
Item
8.01 Other Events.
On
April 7, 2022, FOMO closed on a $15,000 common stock investment in
GenBio, Inc. (https://genbioinc.com/)
bringing its total cash investment in the Company to $65,000. This
includes 65,000 shares and a $25,000 venture debt position
convertible into 25,000 additional shares at a $10 million
valuation. GenBio is currently formulating a proprietary liquid
with anti-inflammatory and reduced blood pressure benefits. When
completed, FOMO and its minority investment Himalaya Technologies,
Inc. (OTC: HMLA; https://www.himalayatechnologies.com/),
which owns 19.9% of GenBio, intend to launch a canned beverage
under the “FOMO” brand with a national beverage company. The “FOMO”
brand has been trademarked for the beverage market in the United
States.
Item
9.01. Exhibits
(a)
Exhibits. The following exhibits are filed with this Current Report
on Form 8-K:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
FOMO
CORP. |
|
|
Date:
April 11, 2022 |
By: |
/s/
Vikram Grover |
|
|
Vikram
Grover |
|
|
Chief
Executive Officer |